| Basics |
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs.
|
| IPO Date: |
April 12, 2006 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$255.19M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.24 | 2.39%
|
| Avg Daily Range (30 D): |
$0.09 | 2.02%
|
| Avg Daily Range (90 D): |
$0.09 | 2.09%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.57M |
| Avg Daily Volume (30 D): |
.43M |
| Avg Daily Volume (90 D): |
.57M |
| Trade Size |
| Avg Trade Size (Sh.): |
143 |
| Avg Trade Size (Sh.) (30 D): |
113 |
| Avg Trade Size (Sh.) (90 D): |
126 |
| Institutional Trades |
| Total Inst.Trades: |
3,116 |
| Avg Inst. Trade: |
$1.5M |
| Avg Inst. Trade (30 D): |
$.52M |
| Avg Inst. Trade (90 D): |
$1.55M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.56M |
| Avg Closing Trade (30 D): |
$.52M |
| Avg Closing Trade (90 D): |
$.66M |
| Avg Closing Volume: |
120.8K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.5
|
$-.09
|
|
Diluted EPS
|
|
$-.5
|
$-.09
|
|
Revenue
|
$
|
$ 50.04M
|
$ 47.65M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -29.49M
|
$ -5.32M
|
|
Operating Income / Loss
|
$
|
$ -41.03M
|
$ -11M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 9.48M
|
$ -.07M
|
|
PE Ratio
|
|
|
|
|
